Clinical Research Directory
Browse clinical research sites, groups, and studies.
Intra-Ovarian PRP Compared With Gonadotropin for Ovarian Response in Letrozole-Resistant PCOS
Sponsor: Bangladesh Medical University
Summary
The goal of this randomized clinical trial is to compare autologous platelet-rich plasma (PRP) with gonadotropin for improving ovarian response in women with letrozole-resistant polycystic ovary syndrome (PCOS). Researchers will compare the two treatments to assess ovarian response, ovulation rates, and pregnancy rates. Participants will be randomly assigned to receive either intra-ovarian autologous PRP or gonadotropin treatment and will be followed for three consecutive cycles.
Official title: Effect of Intra-Ovarian Injection of Autologous Platelet Rich Plasma Compared to Gonadotropin on Ovarian Response in Letrozole Resistant Polycystic Ovary Syndrome
Key Details
Gender
FEMALE
Age Range
18 Years - 35 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2025-06-01
Completion Date
2026-05-28
Last Updated
2026-08-20
Healthy Volunteers
No
Conditions
Interventions
Autologous Platelet-Rich Plasma (PRP)
Participants will receive 5 mL of autologous platelet-rich plasma (PRP) in each ovary by laparoscopy during the proliferative phase of the menstrual cycle. Following the procedure, participants will be monitored for spontaneous ovulation for three consecutive cycles.
Gonadotropin
Participants will receive recombinant follicle-stimulating hormone (rFSH) 75 IU intramuscularly on days 5 and 7 of the menstrual cycle, followed by human menopausal gonadotropin (hMG) 75 IU intramuscularly on days 9 and 11. Follicular development will be monitored by transvaginal ultrasonography. When at least one mature follicle measuring 18-25 mm is identified, ovulation will be triggered with human chorionic gonadotropin (hCG) 5,000 IU intramuscularly, followed by timed intercourse.
Locations (1)
Department of Reproductive Endocrinology and Infertility, Bangladesh Medical University
Dhaka, Dhaka Division, Bangladesh